Skip to main content

Table 1 Baseline demographic and disease characteristics of patients with AS stratified by prior anti-TNF therapy

From: Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy

  Patients with AS (N = 1,250)
    Prior TNF antagonist(s) Reason for discontinuation of prior TNF antagonista
  No prior ETN/IFX Prior ETN and/or IFX IFX only ETN only IFX and ETN Lack of response Loss of response Intolerance
Characteristic (n = 924) (n = 326) (n = 162) (n = 85) (n = 79) (n = 64) (n = 115) (n = 56)
Male (%) 71 72 78 59 72 75 66 68
Age (years; mean ± SD) 44 ± 12 44 ± 11 44 ± 10 44 ± 12 43 ± 10 45 ± 10 42 ± 10 44 ± 13
AS duration (years; mean ± SD) 11 ± 10 11 ± 9 12 ± 9 9 ± 9 11 ± 8 10 ± 9 11 ± 8 12 ± 10
HLA-B27 positive (%) 83 81 80 82 81 86 82 84
Peripheral arthritis (%)b 22 25 26 27 19 23 24 34
Enthesitis (%)c 55 55 52 57 60 50 56 64
Concomitant NSAIDs (%) 77 66 69 57 71 53 68 66
C-reactive protein (mg/dl)d 1.3 1.2 1.4 1.1 1.1 1.4 1.6 0.8
  0.6, 2.6 0.5, 2.6 0.5, 3.0 0.4, 2.2 0.4, 2.6 0.7, 2.8 0.6, 2.7 0.3, 1.7
  1. aNo additional reason except for "other." bOne or more swollen joint count (0 to 44). cOne or more inflamed enthesis in Maastricht Ankylosing Spondylitis Enthesitis Score or fascia plantaris or both. dReference value, 0.4 mg/dl; values listed are median and quartile 1, quartile 3 because of skewed distribution. AS, ankylosing spondylitis; ETN, etanercept; IFX, infliximab; NSAIDs, nonsteroidal antiinflammatory drugs; TNF, tumor necrosis factor.